These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17574687)

  • 21. [Resistance to anti-retroviral therapy in Chilean patients with HIV-1 from 2002 to 2005].
    Afani S A; Orellana R L; Duarte J P; Acevedo M W; Morales B O; Wolff R M; Vásquez P; Beltrán C
    Rev Med Chil; 2007 Oct; 135(10):1237-44. PubMed ID: 18180829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incorporating drug-resistance measurements into the clinical management of HIV-1 infection.
    Zolopa AR
    J Infect Dis; 2006 Sep; 194 Suppl 1():S59-64. PubMed ID: 16921474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioinformatics approach to predicting HIV drug resistance.
    Cordes F; Kaiser R; Selbig J
    Expert Rev Mol Diagn; 2006 Mar; 6(2):207-15. PubMed ID: 16512780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
    Masciotra S; Garrido C; Youngpairoj AS; McNulty A; Zahonero N; Corral A; Heneine W; de Mendoza C; García-Lerma JG
    AIDS; 2007 Nov; 21(18):2503-11. PubMed ID: 18025887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update of the Drug Resistance Mutations in HIV-1.
    Johnson VA; Brun-Vezinet F; Clotet B; Gunthard HF; Kuritzkes DR; Pillay D; Schapiro JM; Richman DD
    Top HIV Med; 2008 Dec; 16(5):138-45. PubMed ID: 19106428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
    McColl DJ; Chappey C; Parkin NT; Miller MD
    Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nine-year trends in clinically relevant reduced susceptibility of HIV-1 to antiretrovirals.
    Sista P; Rinehart A; Wasikowski B; Winters B; Pattery T; Bacheler L
    J Clin Virol; 2009 Mar; 44(3):190-4. PubMed ID: 19168389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
    Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J;
    Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterizing classes of antiretroviral drugs by genotype.
    Foulkes AS; DeGruttola V
    Stat Med; 2003 Aug; 22(16):2637-55. PubMed ID: 12898549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
    Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
    Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mining complex genotypic features for predicting HIV-1 drug resistance.
    Saigo H; Uno T; Tsuda K
    Bioinformatics; 2007 Sep; 23(18):2455-62. PubMed ID: 17698858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
    AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resampling-based analyses of the effects of combinations of HIV genetic mutations on drug susceptibility.
    Schumi J; Degruttola V
    Stat Med; 2008 Oct; 27(23):4740-57. PubMed ID: 18186529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of phenotypic susceptibility to antiretroviral drugs using physiochemical properties of the primary enzymatic structure combined with artificial neural networks.
    Kjaer J; Høj L; Fox Z; Lundgren JD
    HIV Med; 2008 Oct; 9(8):642-52. PubMed ID: 18631257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug resistance among chronic HIV-1-infected patients naïve for use of anti-retroviral therapy in Sao Paulo city.
    Gonsalez CR; Alcalde R; Nishiya A; Barreto CC; Silva FE; de Almeida A; Mendonça M; Ferreira F; Fernandes SS; Casseb J; Duarte AJ
    Virus Res; 2007 Nov; 129(2):87-90. PubMed ID: 17686543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
    Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
    J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic treatment model to examine the association between phenotypic drug resistance and duration of HIV viral suppression.
    Snedecor SJ
    Bull Math Biol; 2005 Nov; 67(6):1315-32. PubMed ID: 16005505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.